14.4 C
Monday, June 17, 2024

Danish deep tech startup nabs $135M in Series B to advance first prophylactic treatments for underserved bleeding and thrombotic disorders

- Advertisement -

Copenhagen-based clinical-stage biotech startup Hemab Therapeutics has successfully raised $135 million in a Series B financing round, which was led by Access Biotechnology and included new investors such as Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity. The startup’s all current investors Novo Holdings, RA Capital Management, and HealthCap also joined the round.

The startup develops the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, and leverages validated advanced technologies and deep insights into the biology of clotting to overcome decades of scientific stagnation. The oversubscribed funding will enable Hemab to complete its ongoing Phase 1/2 clinical study of HMB-001, a bispecific antibody for Glanzmann Thrombasthenia, and initiate pivotal studies. It will also facilitate the start and conclusion of the Phase 1/2 clinical evaluation for HMB-VWF in von Willebrand disease and support the evolution of Hemab’s future pipeline.

“Hemab is fundamentally reimagining the treatment paradigm for underserved bleeding and thrombotic disorders. This financing will allow us to progress our clinical programs for the first prophylactic treatments for Glanzmann Thrombasthenia and von Willebrand Disease, delivering functional cures for patients in need,” said Benny Sorensen, MD, PhD, CEO & President of Hemab. “We’re grateful for this robust syndicate of investors who support our approach of leveraging validated advanced technologies and deep insights into the biology of clotting to overcome decades of scientific stagnation.”

The financing will support Hemab’s scientific and corporate growth plans through 2025, including completion of an ongoing Phase 1/2 clinical study of lead candidate HMB-001 in Glanzmann Thrombasthenia, initiation of pivotal studies, start and completion of Phase 1/2 clinical evaluation for HMB-VWF in von Willebrand disease, and future pipeline evolution in accordance with the company’s Hemab 1-2-5™ strategic guidance—targeting development of 5 clinical assets by 2025.

“Strong investor confidence—in this case, an upsized round and more than $200 million in demand—is a testament to the expertise of the Hemab team, their validated scientific approach, and the opportunity to bring long-overdue innovation to patients living with severe bleeding and thrombotic diseases,” said John Maraganore, PhD, Chair of Hemab’s Board of Directors.

“As founding investor and the company’s largest shareholder, we are excited to support Hemab in the next phase of its plan to build the ultimate clotting company, with a Nordic foundation and global footprint,” said Jørgen Søberg Petersen, MD, PhD, MBA, Partner at Novo Holdings.

Hemab also announced Dan Becker, MD, PhD, Managing Director at Access, and Uya Chuluunbaatar, PhD, Partner at Avoro Ventures, will also join as Directors. Christine Borowski, PhD, Vice President at Access, will join as a Board Observer.

“We are thrilled to partner with Hemab’s exceptional leadership to advance a pipeline of transformative new medicines for areas of high unmet need in hemostatic disorders,” said Dr. Becker.

- Advertisement -
Nurcin Metingil
Nurcin Metingil
A permanent student, a passionate first reader and nowadays doing master’s degree in Publishing Management. Beside these, I am up for games! I have been playing games since I was 6. Now, I am whispering "Business. Business. Numbers. Is this working?"

Related News

Stay Connected


Latest News